287926-06-1

Basic information

• Product Name: 1,3-dimethyl-6-[(1E)-2-phenylethenyl]pteridine-2,4(1H,3H)-dione
• Synonyms: 1,3-dimethyl-6-[(1E)-2-phenylethenyl]pteridine-2,4(1H,3H)-dione
• CAS NO: 287926-06-1
• Molecular Weight: 294.313
• Mol File: 287926-06-1.mol

Chemical Properties

• CAS DataBase Reference: 1,3-dimethyl-6-[(1E)-2-phenylethenyl]pteridine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-dimethyl-6-[(1E)-2-phenylethenyl]pteridine-2,4(1H,3H)-dione(287926-06-1)
• EPA Substance Registry System: 1,3-dimethyl-6-[(1E)-2-phenylethenyl]pteridine-2,4(1H,3H)-dione(287926-06-1)

Safety Data

• Hazardous Substances Data: 287926-06-1(Hazardous Substances Data)

Upstream product

• 287926-09-4 6-(1,2-dibromo-2-phenylethyl)-1,3-dimethylpteridine-2,4(1H,3H)-dione 

Downstream Products

• 287926-09-4 6-(1,2-dibromo-2-phenylethyl)-1,3-dimethylpteridine-2,4(1H,3H)-dione 

Relevant articles and documents

Side-chain transformations of 6- and 7-substituted 1,3-dimethyllumazines (=1,3-dimethylpteridine-2,4(1H,3H)-diones)

A series of side chain reactions starting from the 6- and 7-styryl-substituted 1,3-dimethyllumazines 1 and 21 as well as from the 6- and 7-[2-(methoxycarbonyl)ethenyl]-substituted 1,3-dimethyllumazine 2 and 22 were performed first by addition of Br2

Immunosuppressive effects of pteridine derivatives

Novel poly-substituted pteridinediones (lumazines), and mono- or polysubstituted 2-thiolumazines, 4-thiolumazines or 2,4-dithiolumazines, having disclosed substituents in positions 1, 3, 6 and 7 of the pteridine ring, and pharmaceutically acceptable salts thereof, being represented by the general formula (I). are useful as biologically active ingredients in preparing pharmaceutical compositions especially for the treatment or prevention of a CNS disorder, a cell proliferative disorder, a viral infection, an immune or auto-immune disorder or a transplant rejection. Combinations of the pteridine derivatives of the invention with an immunosuppressant or immunomodulator drug, an antineoplastic drug or an antiviral agent, providing potential synergistic effects, are also disclosed.